ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC)

by biblioteca on 26 de maig de 2026 with No hi ha comentaris

Xu, R.-H., Gomes, D. B. D., Chen, J.-S., Lordick, F., Paulson, A. S., Rha, S. Y., Tabernero, J., Yamaguchi, K., Zhang, J., Aitchison, J., Sun, Z., Zhu, Q., Xia, Y., Jiang, A., Li, X., Rahma, O. E., & Shah, M. A. (2025). ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC). Journal of Clinical Oncology, 43(16_suppl). https://doi.org/10.1200/JCO.2025.43.16_suppl.TPS4204 (Meeting abstract)